Company: GMRE
Filing Date: 2025-03-31
Form Type: DEF 14A
Source: 0001104659-25-029872
Chunk: 49

Company: Global Medical REIT Inc.
Filing Date: 2025-03-31
Form: DEF 14A
Chunk 49
---
 Discussion and Analysis with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the Company’s 2024 Annual Report, and in this Proxy Statement for the 2025 Annual Meeting of Stockholders. 40 Submitted by the Compensation Committee of the Board of Directors. Paula Crowley, Chair
Henry Cole
Ronald Marston Compensation Committee Interlocks and Insider Participation No current or former member of the Compensation Committee is, or has been, one of our employees or officers. None of our executive officers currently serves, or during the past fiscal year has served, as a member of the Board of Directors or compensation committee of another entity that has one or more executive officers serving on our Board of Directors or Compensation Committee. Risk Considerations in our Executive Compensation Program The Compensation Committee has reviewed its compensation policies and practices with respect to employees of the Company, taking into consideration risk management practices and risk-taking incentives. Following such review, we determined that our compensation policies and practices for such employees do not create risks that are reasonably likely to have a material adverse effect on us. Several features of the Company’s equity compensation program and policies are designed to reduce the likelihood of excessive risk-taking by employees, including:

| ● | Our                                                                                       
 performance-based compensation is structured to reward both short-and long-term corporate 
 performance;                                                                              |

| ● | The                                                                      
 payout amounts under our short-term and long-term incentives are capped; |

| ● | The                                                                                       
 Compensation Committee considers risk management when determining the portion of our 2024 
 Annual Incentive Plan earned for individual performance; and                              |

| ● | A                                                                                    
 Clawback Policy which subjects certain portions of our executives’ pay to recoupment 
 by the Company in the event of a Restatement (as defined in the Clawback Policy).    |

41 SUMMARY COMPENSATION TABLE FOR 2024, 2023 AND 2022 The Summary Compensation Table below contains, in compliance with the reporting requirements of the SEC, the compensation information for our NEOs for the years ended December 31, 2024, 2023 and 2022. Equity compensation is reported in several different tables in this Proxy Statement. For that reason, investors should take care to not “double count” equity awards.

| Name                          
 and Principal Position        |     | Year |     | Salary |         |     | Stock  
 Awards |           | (1) |     | Non-Equity     
 Incentive Plan 
 Compensation